SAN FRANCISCO (TheStreet) -- While you were (hopefully) enjoying some time off this weekend, I was sitting in a convention center here writing about biotech and drug companies presenting new data on blood-related cancers and diseases at the American Society of Hematology (ASH) annual meeting.
Don't feel too bad for me. I did manage to sneak some fun time in the City by the Bay, in between writing about lymphoma, leukemia and beta-thalassemia. It's Monday, so all those ASH biotech and drug stocks are about to start trading. Here's a cheat sheet for what you need to know.
1. The Agios Pharmaceuticals (AGIO) AG-221 data in relapsed/refractory acute myeloid leukemia were presented to a standing room crowd on Sunday afternoon. This was definitely a highlight of the ASH meeting. The genetic mutations responsible for cancer are being turned on their head to create highly targeted and effective medicines. And because these targeted drugs are matched to suitable patients, clinical development moves fast. Pivotal studies designed to get AG-221 approved will be started next year, Agios and partner Celgene (CELG) announced.
If there's a debate among investors about Agios coming out of this weekend's ASH meeting, it's probably around what to do with a valuation that might be getting a bit stretched due to incredible performance of the stock this year. If there's a post-ASH sell off, I expect the dips to be bought by people who missed Agios' run the first time.
2. The new form of cancer immunotherapy known as CAR-T continues to post amazing results in B-cell cancers. I wrote about the 90%-plus cure rate seen in kids with agressive form of leukemia following treatment with a CAR-T therapy developed by the University of Pennsylvania and Novartis (NVS) .